Total Payments
$11,756
2024 Payments
$259.78
Companies
14
Transactions
38
Medicare Patients
825
Medicare Billing
$78,467
Payment Breakdown by Category
Consulting$5,865 (49.9%)
Other$3,800 (32.3%)
Food & Beverage$2,091 (17.8%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Consulting Fee | $5,865 | 4 | 49.9% |
| Honoraria | $3,800 | 1 | 32.3% |
| Food and Beverage | $2,091 | 33 | 17.8% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| UROGEN PHARMA, INC. | $4,245 | 11 | $0 (2024) |
| Merck Sharp & Dohme Corporation | $3,075 | 3 | $0 (2020) |
| Janssen Biotech, Inc. | $1,734 | 3 | $0 (2023) |
| E.R. Squibb & Sons, L.L.C. | $1,230 | 1 | $0 (2021) |
| Photocure Inc | $484.74 | 4 | $0 (2018) |
| Astellas Pharma US Inc | $281.96 | 4 | $0 (2021) |
| Boston Scientific Corporation | $224.37 | 3 | $0 (2024) |
| Galil Medical Inc. | $112.50 | 1 | $0 (2018) |
| Cook Incorporated | $100.80 | 1 | $0 (2017) |
| Janssen Research & Development, LLC | $100.00 | 2 | $0 (2022) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $259.78 | 8 | UROGEN PHARMA, INC. ($101.85) |
| 2023 | $5,838 | 8 | UroGen Pharma, Inc. ($4,092) |
| 2022 | $131.36 | 3 | Janssen Research & Development, LLC ($100.00) |
| 2021 | $1,328 | 3 | E.R. Squibb & Sons, L.L.C. ($1,230) |
| 2020 | $3,000 | 2 | Merck Sharp & Dohme Corporation ($3,000) |
| 2019 | $302.10 | 4 | Boston Scientific Corporation ($147.02) |
| 2018 | $437.86 | 4 | Astellas Pharma US Inc ($168.58) |
| 2017 | $458.17 | 6 | Photocure Inc ($327.96) |
All Payment Transactions
38 individual payment records from CMS Open Payments — Page 1 of 2
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/19/2024 | UROGEN PHARMA, INC. | JELMYTO (Drug) | Food and Beverage | In-kind items and services | $36.78 | General |
| Category: UROTHELIAL CANCER | ||||||
| 09/15/2024 | Janssen Scientific Affairs, LLC | BALVERSA (Drug) | Food and Beverage | In-kind items and services | $38.94 | General |
| Category: Oncology | ||||||
| 09/13/2024 | Janssen Scientific Affairs, LLC | BALVERSA (Drug) | Food and Beverage | In-kind items and services | $41.64 | General |
| Category: Oncology | ||||||
| 08/27/2024 | UROGEN PHARMA, INC. | JELMYTO (Drug) | Food and Beverage | In-kind items and services | $23.57 | General |
| Category: UROTHELIAL CANCER | ||||||
| 06/20/2024 | Boston Scientific Corporation | LithoVue (Device) | Food and Beverage | In-kind items and services | $44.98 | General |
| Category: LithoVue_URO | ||||||
| 06/19/2024 | Boston Scientific Corporation | LithoVue (Device) | Food and Beverage | In-kind items and services | $32.37 | General |
| Category: LithoVue_URO | ||||||
| 04/09/2024 | UROGEN PHARMA, INC. | JELMYTO (Drug) | Food and Beverage | In-kind items and services | $16.51 | General |
| Category: UROTHELIAL CANCER | ||||||
| 02/08/2024 | UROGEN PHARMA, INC. | JELMYTO (Drug) | Food and Beverage | In-kind items and services | $24.99 | General |
| Category: UROTHELIAL CANCER | ||||||
| 12/04/2023 | Janssen Biotech, Inc. | — | Consulting Fee | Cash or cash equivalent | $1,635.00 | General |
| 12/01/2023 | UroGen Pharma, Inc. | — | Honoraria | Cash or cash equivalent | $3,800.00 | General |
| 12/01/2023 | UroGen Pharma, Inc. | — | Food and Beverage | In-kind items and services | $234.93 | General |
| 11/18/2023 | Janssen Biotech, Inc. | ERLEADA (Drug) | Food and Beverage | In-kind items and services | $53.40 | General |
| Category: Oncology | ||||||
| 09/24/2023 | Astellas Pharma Global Development | Padcev (Drug) | Food and Beverage | In-kind items and services | $57.94 | General |
| Category: Oncology | ||||||
| 03/16/2023 | UroGen Pharma, Inc. | JELMYTO (Drug) | Food and Beverage | In-kind items and services | $5.78 | General |
| Category: UROTHELIAL CANCER | ||||||
| 01/16/2023 | UroGen Pharma, Inc. | JELMYTO (Drug) | Food and Beverage | In-kind items and services | $28.53 | General |
| Category: UROTHELIAL CANCER | ||||||
| 01/05/2023 | UroGen Pharma, Inc. | JELMYTO (Drug) | Food and Beverage | In-kind items and services | $22.82 | General |
| Category: UROTHELIAL CANCER | ||||||
| 08/11/2022 | UroGen Pharma, Inc. | JELMYTO (Drug) | Food and Beverage | In-kind items and services | $31.36 | General |
| Category: UROTHELIAL CANCER | ||||||
| 01/12/2022 | Janssen Research & Development, LLC | — | Food and Beverage | In-kind items and services | $50.00 | General |
| 01/12/2022 | Janssen Research & Development, LLC | — | Food and Beverage | In-kind items and services | $50.00 | General |
| 12/03/2021 | Astellas Pharma US Inc | XTANDI (Drug) | Food and Beverage | In-kind items and services | $78.58 | General |
| Category: ONCOLOGY | ||||||
| 08/12/2021 | UROGEN PHARMA, INC. | JELMYTO (Drug) | Food and Beverage | In-kind items and services | $19.74 | General |
| Category: UROTHELIAL CANCER | ||||||
| 03/04/2021 | E.R. Squibb & Sons, L.L.C. | OPDIVO (Biological) | Consulting Fee | Cash or cash equivalent | $1,230.00 | General |
| Category: Oncology | ||||||
| 12/11/2020 | Merck Sharp & Dohme Corporation | — | Consulting Fee | Cash or cash equivalent | $1,500.00 | General |
| 07/15/2020 | Merck Sharp & Dohme Corporation | — | Consulting Fee | Cash or cash equivalent | $1,500.00 | General |
| 12/06/2019 | Janssen Biotech, Inc. | Erleada (Drug) | Food and Beverage | In-kind items and services | $45.56 | General |
| Category: Oncology | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 12 | 325 | 439 | $111,380 | $29,725 |
| 2022 | 10 | 225 | 304 | $33,056 | $17,937 |
| 2021 | 6 | 131 | 199 | $36,826 | $13,223 |
| 2020 | 7 | 144 | 227 | $61,321 | $17,582 |
Total Patients
825
Total Services
1,169
Medicare Billing
$78,467
Procedure Codes
35
All Medicare Procedures & Services
35 procedure records from CMS Medicare Utilization — Page 1 of 2
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 52000 | Diagnostic exam of bladder and urethra using an endoscope | Facility | 2023 | 82 | 155 | $19,481 | $8,403 | 43.1% |
| 52235 | Destruction and/or removal of growth of bladder and urethra using an endoscope, 2.0-5.0 cm | Facility | 2023 | 16 | 18 | $19,926 | $3,831 | 19.2% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Facility | 2023 | 62 | 69 | $4,789 | $3,330 | 69.5% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Facility | 2023 | 22 | 22 | $4,466 | $3,085 | 69.1% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Facility | 2023 | 32 | 41 | $4,504 | $2,877 | 63.9% |
| 52234 | Destruction and/or removal of growth of bladder and urethra using an endoscope, 0.5-2.0 cm | Facility | 2023 | 12 | 13 | $12,285 | $2,161 | 17.6% |
| 52332 | Insertion of stent in ureter using an endoscope | Facility | 2023 | 13 | 19 | $38,140 | $1,894 | 5.0% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Facility | 2023 | 15 | 15 | $2,436 | $1,446 | 59.4% |
| 99442 | Telephone medical discussion with physician, 11-20 minutes | Facility | 2023 | 22 | 28 | $1,947 | $1,332 | 68.4% |
| 99212 | Established patient office or other outpatient visit, 10-19 minutes | Facility | 2023 | 19 | 20 | $851.00 | $523.45 | 61.5% |
| 74420 | Imaging of urinary tract following injection of a contrast agent | Facility | 2023 | 14 | 23 | $1,955 | $435.40 | 22.3% |
| 99441 | Telephone medical discussion with physician, 5-10 minutes | Facility | 2023 | 16 | 16 | $600.00 | $407.25 | 67.9% |
| 52000 | Diagnostic exam of bladder and urethra using an endoscope | Facility | 2022 | 65 | 119 | $14,716 | $7,129 | 48.4% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Facility | 2022 | 28 | 28 | $4,471 | $2,537 | 56.7% |
| 99443 | Telephone medical discussion with physician, 21-30 minutes | Facility | 2022 | 18 | 23 | $2,438 | $1,696 | 69.5% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Facility | 2022 | 11 | 11 | $2,227 | $1,518 | 68.2% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Facility | 2022 | 24 | 28 | $2,118 | $1,369 | 64.6% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Facility | 2022 | 14 | 16 | $1,883 | $1,234 | 65.5% |
| 99442 | Telephone medical discussion with physician, 11-20 minutes | Facility | 2022 | 19 | 20 | $1,449 | $1,044 | 72.1% |
| 99441 | Telephone medical discussion with physician, 5-10 minutes | Facility | 2022 | 21 | 23 | $987.00 | $589.41 | 59.7% |
| 74420 | Imaging of urinary tract following injection of a contrast agent | Facility | 2022 | 13 | 23 | $2,251 | $450.49 | 20.0% |
| 99212 | Established patient office or other outpatient visit, 10-19 minutes | Facility | 2022 | 12 | 13 | $516.00 | $370.58 | 71.8% |
| 52000 | Diagnostic examination of the bladder and bladder canal (urethra) using an endoscope | Facility | 2021 | 55 | 97 | $12,254 | $5,643 | 46.0% |
| 52235 | Destruction and/or removal of (2.0 to 5.0 centimeters) medium growths of the bladder and bladder canal (urethra) using an endoscope | Facility | 2021 | 14 | 16 | $17,232 | $3,550 | 20.6% |
| 99442 | Physician telephone patient service, 11-20 minutes of medical discussion | Facility | 2021 | 22 | 30 | $2,430 | $1,618 | 66.6% |
About Dr. Peter Clark, MD
Dr. Peter Clark, MD is a Urology healthcare provider based in Charlotte, North Carolina. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 11/21/2005. The National Provider Identifier (NPI) number assigned to this provider is 1073595401.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Peter Clark, MD has received a total of $11,756 in payments from pharmaceutical and medical device companies, with $259.78 received in 2024. These payments were reported across 38 transactions from 14 companies. The most common payment nature is "Consulting Fee" ($5,865).
As a Medicare-enrolled provider, Clark has provided services to 825 Medicare beneficiaries, totaling 1,169 services with total Medicare billing of $78,467. Data is available for 4 years (2020–2023), covering 35 distinct procedure/service records.
Ad
Practice Information
- Specialty Urology
- Location Charlotte, NC
- Active Since 11/21/2005
- Last Updated 07/15/2024
- Taxonomy Code 208800000X
- Entity Type Individual
- NPI Number 1073595401
Products in Payments
- OPDIVO (Biological) $1,230
- Cysview (Drug) $484.74
- JELMYTO (Drug) $210.08
- XTANDI (Drug) $193.83
- GENERAL THERAPIES (Device) $147.02
- VISUAL-ICE (Device) $112.50
- Cook Medical Urology (Device) $100.80
- BALVERSA (Drug) $80.58
- LithoVue (Device) $77.35
- KEYTRUDA (Biological) $74.72
- Padcev (Drug) $57.94
- ERLEADA (Drug) $53.40
- Erleada (Drug) $45.56
- Xofigo (Drug) $17.38
- DAV-Arista AH (Device) $12.03
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Urology Doctors in Charlotte
Manish Patel, Md, MD
Urology — Payments: $96,196
Urology $96,196
Maxim Mckibben, Md, MD
Urology — Payments: $65,968
Urology $65,968
Dr. Todd Cohen, Md, MD
Urology — Payments: $45,786
Urology $45,786
Ornob Roy, Md, MD
Urology — Payments: $23,890
Urology $23,890
Dr. Samuel Peretsman, M.d, M.D
Urology — Payments: $16,135
Urology $16,135
Nicholas Fitzsimons, Md, MD
Urology — Payments: $15,091
Urology $15,091